Context: Leiomyomas have abundant extracellular matrix (ECM), with upregulation of versican, a large proteoglycan.
U terine leiomyomas are the most commonly occurring pelvic tumors (1) , affecting 70% to 80% of premenopausal women (2) . Abnormal uterine bleeding, pelvic pain and pressure, and diverse adverse reproductive outcomes are attributable to leiomyomas in 20% to 40% of women over 35 years of age (3), contributing to significant impairment of their quality of life (4) .
The precise molecular basis of leiomyoma pathogenesis is unknown, although specific genetic changes and the hormonal milieu clearly have an important role (5) . Overproduction of disorganized extracellular matrix (ECM) is an established phenomenon in leiomyomas and is believed to be a major contributor to their growth and thus to their clinical manifestations (6, 7) . The large chondroitin sulfate (CS) proteoglycan versican, which is located in the pericellular ECM of cells as well as the leiomyoma interstitial ECM, is reported to be overexpressed in leiomyoma (8) (9) (10) (11) . Versican overexpression in cultured leiomyoma cells, as compared with myometrium cells, is a distinguishing characteristic of leiomyoma cells, but little is known about versican turnover in leiomyoma (12) . The ADAMTS (a disintegrin-like and metalloprotease with thrombospondin type 1 motifs) proteases are a family of 18 secreted metalloproteinases, of which six cleave versican (ADAMTS1, -4, -5, -9, -15, and -20), in several contexts (13) (14) (15) (16) . Proteolytic cleavage removes versican during tissue remodeling and generates a bioactive N-terminal G1 domain-containing fragment from the versican V1 variant termed versikine (17) . Additionally, growthpromoting effects have been described for versican or its G3 domain (18) . Of the four major versican splice isoforms, primarily V0 and V1 are reported to be expressed in leiomyoma (10) . V0 and V1 are each susceptible to cleavage by ADAMTS proteases, which target specific peptide bonds, such as Glu 405 -Gln 406 within the GAG-a domain in V0/V2
and Glu 441 -Ala 442 within the GAG-b domain in V1 (the corresponding site in versican V0 is Glu 1428 -Ala 1429 ) (15, 19, 20) . The current medical treatment option approved by the US Food and Drug Administration for women with symptomatic leiomyoma is leuprolide acetate, a gonadotropin-releasing hormone agonist. Leuprolide acetate suppresses estrogen, which is permissive for leiomyoma growth via induction of progesterone receptors, and is effective in reducing leiomyoma size in preparation for surgery, which it may do by impeding ECM production (including versican) (21) . However, side effects related to hypoestrogenism limit its extended use. Another agent under study that reduces leiomyoma ECM expansion is 1,25-dihydroxyvitamin D3 (22, 23) , which reduces the expression of proteoglycans including versican and of the profibrogenic factor transforming growth factor-b in a human leiomyoma cell line (23) .
Versican proteolysis in leiomyoma has not been previously investigated despite its significance in other contexts (24) . The findings of this study are relevant to the pathogenesis of leiomyoma and for new therapeutic directions.
Materials and Methods

Tissue collection
Myometrium and leiomyoma tissues were obtained from 14 women between the ages of 43 and 60 years who underwent a hysterectomy between January 2015 and February 2016. The leiomyoma were intramural or subserosal. Women using hormonal therapies at the time of surgery were excluded. The women were grouped by the indication for their hysterectomy [either symptomatic leiomyoma, such as pelvic pain or heavy menstrual bleeding, or asymptomatic leiomyoma (i.e., hysterectomy for indications unrelated to incidentally detected leiomyoma), such as urinary incontinence or pelvic organ prolapse]. Additional subject characteristics are described in Table 1 . Three tissue samples were collected from each subject's myometrium and leiomyoma for histology, RNA, and protein analysis with approval of the Cleveland Clinic Institutional Review Board (Study number: 14-1603).
Antibodies
Rabbit polyclonal antibodies anti-DPEAAE (PA1-1748A; Thermo Scientific, Waltham, MA) (dilution of 1:1000 and 1:200 for western blotting and immunostaining, respectively) and anti-Vc rabbit polyclonal antibody (detecting versican V0 and V1; dilution of 1:1000 and 1:200 for western blotting and immunostaining, respectively) were previously described (25) . Rabbit antiserum specific for the new C terminus generated by cleavage of the Glu 405 -Gln 406 peptide bond of versican V0/V2 (anti-NIVSFE, antiserum also known as JSCNIV) was kindly provided by Dr. John Sandy (Rush Medical Center, Chicago, IL) and was used at a dilution of 1:200 for immunostaining (19) . A neoepitope antibody was generated against the new N-terminus generated by ADAMTS versican V1 cleavage at the Glu 441 -Ala 442 site (i.e., 442 ARRGQF, V1 sequence enumeration). Briefly, the synthetic peptide ARRGQFGGC was conjugated to keyhole limpet hemocyanin via the Cys residue and used to immunize rabbits. Antisera were affinity purified against the immobilized immunogen peptide, and activity against uncleaved versican was removed by affinity with peptide CTVPKDPEAAEARRG. The resulting antibody (named anti-ARRGQF; dilution of 1:200 for immunostaining) was tested by enzyme-linked immunosorbent assay and was specific for the ARRGQF end-epitope with minimal reactivity to intact versican. Antibodies specific for a-smooth muscle actin (SMA; 1:1000) (A2547; Sigma-Aldrich, St. Louis, MO), phosphohistone H3 (1:500) (06-570; EMD Millipore, Darmstadt, Germany), and cleaved caspase-3 (1:500) (9661; Cell Signaling Technologies, Danvers, MA) were used for immunofluorescence analysis of cells.
Cell lines and small interfering RNA treatment
Immortalized human uterine smooth muscle (UtSMChTERT) and uterine leiomyoma (UtLM-hTERT) cell lines generated by transfection with human telomerase were kindly provided by Dr. Darlene Dixon (National Institute of Environmental Health Sciences, Research Triangle Park, NC) and were cultured as previously described (26) . For RNA silencing, UtLM-hTERT cells cultured in 6-well plates were transfected at 70% confluence with 5 nM VCAN short interfering RNAs (siRNAs) [Silencer select s229335 (siRNA 1) and Silencer 14606 (siRNA 2); Ambion, Waltham, MA] or with a nontargeting (control) siRNA (4390843; Ambion) using Lipofectamine RNAiMAX (13778; Invitrogen, Carlsbad, CA). Fifty-two hours after transfection, the medium was collected, and the cell layer was lysed using radioimmunoprecipitation assay buffer.
Histology, immunofluorescence, and RNA in situ hybridization
Tissue blocks 1 cm 3 1 cm in size and ;1 g in weight were dissected from hysterectomy specimens submitted for histopathology analysis, fixed in 4% paraformaldehyde in phosphate-buffered saline at 4°C overnight, and embedded in paraffin. Sections (7 mm thick) were used for hematoxylin and eosin staining and for immunofluorescence. An indirect immunofluorescence method was used with the versican antibodies listed previously as the primary antibodies, and a goat anti-rabbit antibody (1735088; Life Technologies, Eugene, OR) was used as the secondary antibody (1:200 dilution). The sections were pretreated with chondroitinase ABC (0.05 U/mL, 1:200 dilution) (C3667; Sigma-Aldrich) for 30 minutes at room temperature.
The RNAScope method (Advanced Cell Diagnostics, Newark, CA) was used for in situ hybridization (ISH) with specific probes targeting VCAN exon 7 (452231 Red) or exon 8 (452241 Red) (encoding the GAG-a and GAG-b domains, respectively). Paraffin sections (7 mm) were cut immediately prior to ISH, deparaffinized, and hybridized to the probes using the RNAScope 2.0 HD Red detection kit and HybEZ oven (Advanced Cell Diagnostics) according to the manufacturer's instructions. Sections were counterstained with Gill's hematoxylin (26030; Electron Microcopy Sciences, Hatfield, PA).
Western blot
Myometrium and leiomyoma tissue stored at 280°C was homogenized (Ultra Turrax T2; IKA, Wilmington, NC) in lysis buffer [0.1% NP-40 (74385; Sigma-Aldrich), 0.01% sodium dodecyl sulfate (71725; Sigma-Aldrich), and 0.05% sodium deoxycholate (D6750; Sigma-Aldrich) in phosphate-buffered saline] and Halt Protease Inhibitor Cocktail (1860932; Thermo Scientific). The tissue lysate was centrifuged at 14,000 rpm for 5 minutes, and the cleared supernatant was used for western blotting. UtSMC-hTERT and UtLM-hTERT serum-free conditioned medium was collected, and the cell layer was extracted using lysis buffer. Extracts and media were analyzed by 7.5% or 4% to 20% gradient reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis. Chondroitinase ABC pretreatment (0.05 U/mL) of all tissue and cell extracts and media was performed for 2 hours at 37°C prior to electrophoresis to eliminate CS chains attached to versican core protein. Proteins were electroblotted to Immobilon-FL transfer membranes (IPFL00010; EMD Millipore, Darmstadt, Germany), incubated with each primary antibody overnight at 4°C and then with IRDye secondary antibody (LI-COR Biosciences, Lincoln, NE) for 1 hour at room temperature. The Odyssey Imaging System (LI-COR Biosciences) was used for detection and quantitative analysis.
Quantitative real-time polymerase chain reaction
Myometrium (100 mg) and leiomyoma tissue were placed in TRIzol Reagent (15596018; Invitrogen) and stored at 280°C prior to RNA isolation. RNA was isolated from UtSMC-hTERT and UtLM-hTERT cell monolayer cultures harvested at 90% confluence using TRIzol. For reverse transcription, 2 mg RNA was used to generate cDNA (SuperScript III Cells direct cDNA synthesis system 46-6321; Invitrogen). The cDNA was diluted 1:5 and used for quantitative reverse transcription polymerase chain reaction (qRT-PCR) with primers specific for versican splice variants, ADAMTS protease genes, smooth muscle markers, or b-actin (Invitrogen) (Supplemental Table 1 ) and Bullseye EvaGreen qPCR MasterMix (BEQPCR-S; MidSci, Valley Park, MO) in a Touch Real-Time PCR Detection System (CFX96; BioRad, Hercules, CA).
Semiquantitative polymerase chain reaction
Polymerase chain reaction (PCR) products obtained after 30 cycles were electrophoresed on 2% agarose gels using a Gel Logic 100 Imaging System (Kodak, Rochester, NY). The cycle number was established by performing semiquantitative PCR at 
Statistical analysis
Fisher's exact test was used to analyze categorical data in our research population such as race, parity, indication for surgery and size of leiomyoma. The Wilcoxon rank sum test was used to determine the difference between age and preoperative hemoglobin between the symptomatic and asymptomatic groups. Quantification of mRNA expression was performed using the ΔΔCt method. Student t test was used to determine the statistical significance of differences between two cell lines or two groups of tissues. Statistical significance was established at P , 0.05.
Results
Patient population
Surgical specimens were obtained from 14 women undergoing total hysterectomies. The women with symptomatic leiomyoma were more likely to have heavy menstrual bleeding (n = 7; P , 0.01), whereas the women with incidental asymptomatic leiomyoma had hysterectomies for urinary incontinence (n = 5; P = 0.02) and pelvic organ prolapse (n = 1; P = 0.03) ( Table 1 ). The patient with pelvic pain in the asymptomatic group had pelvic pain due to previously diagnosed endometriosis and not leiomyoma. Indeed, the pelvic pain persisted after hysterectomy. The two groups of women were similar in age (P = 0.11), race (P = 0.59), parity (P = 0.46) and menopausal status (P = 0.07). The group with symptomatic leiomyoma had significantly larger leiomyomas (P , 0.01) and lower hemoglobin (P = 0.02) than the asymptomatic group.
Human myometrium and leiomyoma robustly express VCAN splice variants containing exon 7 and/or exon 8
Hematoxylin and eosin staining of myometrium revealed well-organized bundles of smooth muscle cells, whereas the leiomyomas appeared disorganized with more evident ECM [ Fig. 1(a) ]. To identify versican isoforms expressed by myometrial and leiomyoma tissue and the cell types expressing them, we used RNA ISH and qRT-PCR. ISH demonstrated robust, ubiquitous expression of VCAN isoforms containing exon 7 and/or exon 8 in myometrial and leiomyoma cells [ Fig. 1(a) ]. We conclude that VCAN transcripts encoding isoforms V0 (containing exon 7-encoded and exon 8-encoded GAG-a and GAG-b regions, respectively) and V1 (containing only the exon 8-encoded GAG-b) are abundant in myometrium and leiomyoma and are expressed by both myometrial smooth muscle cells and leiomyoma cells. That VCAN isoforms V2 and V3 were not expressed at notable levels in either tissue type was demonstrated by semiquantitative RT-PCR of the UtSMC-hTERT and UtLM-hTERT cell lines where V2 was detected to a lesser degree and V3 was not detected (Supplemental Fig. 1) .
qRT-PCR comparing expression of VCAN isoforms in myometrium from the asymptomatic versus symptomatic groups revealed a significantly higher relative fold-change of V0 mRNA (3.85; P = 0.03) in the symptomatic women [ Fig. 1(b) ]. VCAN V1 (P = 0.39) and V2 (P = 0.54) mRNAs were unchanged. In contrast, in leiomyoma from asymptomatic and symptomatic cohorts, the fold change was 4.4 (P = 0.03) for V0, 6.1 (P = 0.04) for V1, and 1.7 (P = 0.42) for V2. mRNA levels for VCAN V0 and V1 in myometrium and leiomyoma tissue were compared in the symptomatic and asymptomatic women (Supplemental Table 2 ). Overall, there was a 10.3-fold greater increase in V1 mRNA expression in leiomyoma than in https://academic.oup.com/jcemmyometrium (P = 0.004) but not in V0 (1.6-fold; P = 0.19) or V2 mRNA (1.2-fold; P = 1.19). When comparing leiomyoma with myometrium, we found that symptomatic women had a greater difference in mRNA levels of VCAN V1 (2.5-fold; P = 0.03) than the asymptomatic leiomyoma group (Supplemental Table 3 ).
Abundant cleaved versican is present in leiomyoma and myometrium
The localization of versican and its ADAMTS protease-derived cleavage products was determined in tissues by immunofluorescence and the abundance and molecular forms of versican were determined by western blotting. The antibodies that were used reacted with versican GAG-b domain (anti-Vc) or were neoepitope antibodies specific for the new C-and N-termini generated by ADAMTS cleavage of versican GAG-b domain (anti-DPEAAE and anti-ARRGQF, respectively) or the new C-terminus generated in the versican GAG-a domain (anti-NIVSFE) [ Fig. 2(a) ]. Immunostaining of myometrium and leiomyoma sections demonstrated anti-Vc staining throughout, with more intense staining in the leiomyomas [ Fig. 2(b) ]. Anti-DPEAAE and anti-ARRGQF antibodies gave robust staining that was also stronger in leiomyomas [ Fig. 2(b) ]. Although there was considerable variation of staining intensity from region to region within each specimen, we observed stronger immunofluorescence signals in leiomyoma than myometrium sections with each antibody, with the exception of NIVSFE, which stained all sections comparatively lightly [ Fig. 2(b) ].
Under the extraction conditions used, western blot analysis using anti-Vc typically did not identify intact versican V0 or V1, despite prior digestion of the extracts with chondroitinase ABC to remove their CS chains, which retard in-gel migration. Intact versican V0 or V1 migrate at ;450 kDa and ;350 kDa, respectively, and were seen in some instances (e.g., leiomyoma, subject 3) [ Fig. 3(a) ]. The neo-epitope antibodies used here (anti-DPEAAE, anti-ARRGQF, and anti-NIVSFE) specifically detect the end-epitopes generated by ADAMTS proteolysis. Indeed, western blotting with anti-Vc, which detects intact and cleaved versican, and anti-DPEAAE consistently demonstrated major species of 70 kDa and 50 kDa, indicating significant cleavage of versican [ Fig. 3(a) and 3(b) ]. An expected ;140 kDa fragment corresponding to proteolytic cleavage at Glu Western blots of matched myometrium and leiomyoma from three symptomatic patients demonstrate a distinct 70-kDa band using anti-Vc and 70-kDa and 50-kDa bands with anti-DPEAAE. Intact versican was not seen using the anti-Vc antibody, given the absence of bands at 450 kDa (versican V0) and 350 kDa (versican V1). (c) Significantly higher expression of ADAMTS4 (P = 0.006) and ADAMTS9 (P = 0.02) mRNAs was detected in the myometrium of the symptomatic group as compared with the asymptomatic group. (d) In leiomyomas from symptomatic participants, higher levels of ADAMTS4 (P = 0.03) and ADAMTS15 (P = 0.04) mRNAs were detected. Asx, asymptomatic; Sym, symptomatic. *P , 0.05. Statistical significance was calculated using Student t test.
this fragment was not generated, was further processed (e.g., to the observed 50-kDa fragment), or was not isolated from tissue under the extraction conditions used. Neither anti-ARRGQF nor anti-NIVSFE gave a signal on western blots, suggesting that the fragments generated by ADAMTS proteases may have been further degraded by other proteases.
Versican-degrading ADAMTS proteases are expressed in myometrium and leiomyoma
Several ADAMTS proteases were previously shown to cleave versican (24) . Their mRNA levels were quantified in myometrium and leiomyoma using qRT-PCR to determine whether they participate in the observed proteolysis of versican. Comparison of their mRNA expression in myometrium from asymptomatic subjects with symptomatic subjects revealed higher expression of ADAMTS4 (5.9-fold; P = 0.006) and ADAMTS9 (4.4-fold; P = 0.02) but not ADAMTS15 (4.3-fold; P = 0.065) [ Fig. 3(c) ]. Higher mRNA levels of two ADAMTS genes [ADAMTS4 (8.2-fold; P = 0.03) and ADAMTS15 (9.1-fold; P = 0.04)] were seen in the symptomatic leiomyomas when compared with asymptomatic leiomyomas, but the observed ADAMTS9 mRNA changes were not significant (8.2-fold; P = 0.061) [ Fig. 3(d) ]. ADAMTS1 and ADAMTS5 mRNAs were not significantly different in the asymptomatic versus symptomatic myometrium or leiomyoma (P = 0.91 and P = 0.29, respectively), and ADAMTS20 was not expressed in either myometrium or leiomyoma. The difference in ADAMTS15 mRNA expression between leiomyoma and myometrium (3.38-fold; P = 0.04) was greater in the symptomatic leiomyoma group compared with the asymptomatic group (Supplemental Table 3 ).
Versican is extensively proteolyzed in UtSMC-hTERT and UtLM-hTERT cells
Both UtSMC-hTERT and UtLM-hTERT cell lines expressed VCAN splice isoforms [ Fig. 4(a) ] and ADAMTS genes [ Fig. 4(b) ]. The UtLM-hTERT cell line Fig. 1 ), and were therefore not considered further. Of the ADAMTS mRNAs evaluated, ADAMTS15 was highly expressed in UtLM-hTERT (P = 0.03), whereas the UtSMC-hTERT cell line had significantly higher expression of ADAMTS5 (P = 0.005) and ADAMTS9 (P = 0.002) [ Fig. 4(b) ]. ADAMTS1 (P = 0.07) and ADAMTS4 (P = 0.10) mRNAs were not significantly different between the cell lines, and ADAMTS20 was not expressed by either line. UtSMC-hTERT and UtLM-hTERT lysates (inclusive of cells and their ECM) and medium were analyzed by western blotting using versican antibodies. As in the tissue samples, neither cell lysate nor the cell media contained significant levels of intact versican (detected by anti-Vc). Consistent with the observation in tissue extracts, cleaved versican (70 kDa) was consistently detected using anti-Vc [Fig. 4(c) ] and anti-DPEAAE [ Fig. 4(d) ]. Each antibody gave greater reactivity in the UtLM-hTERT cell extracts [ Fig. 4(c) and 4(d) ]. The presence of cleaved versican in the cell lysate, which also contains cell-associated ECM, suggests that it was present in the pericellular matrix or intracellularly.
VCAN siRNA eliminates versican cleavage products and reduces sex steroid receptor expression in UtLM-hTERT Given the high levels of cleaved versican and expression of ADAMTS genes detected in leiomyoma and the UtLMhTERT cells, we sought to determine whether the cleaved versican, previously shown to be bioactive in the context of embryonic interdigital web regression (17) and multiple myeloma (27) , could affect their biology. Because collective knockdown of several versican-degrading ADAMTS proteases was not feasible and because only cleaved but not intact versican was detected, we used VCAN siRNA to determine the effect of the absence of versican fragments on the UtLM-hTERT cells.
Both siRNAs that we used successfully knocked down VCAN mRNA, as determined by qRT-PCR, with a 93% reduction in VCAN expression by siRNA1 [ Fig. 5(a) ] and an 88% reduction by siRNA2 (data not shown) compared with the control siRNA. Therefore, we performed subsequent experiments using siRNA1. VCAN siRNA1-transfected cells demonstrated a near total loss of immunoreactive versican in western blotting of the lysate and medium using anti-Vc [ Fig. 5(b) ]. This is indicative of the efficacy of knockdown and validates the specificity of the anti-versican antibodies used in this study. VCAN siRNA-transfected cells were morphologically similar to those transfected with the control siRNA. Markers of the smooth muscle phenotype were analyzed by qRT-PCR to determine whether there was a change in the cell phenotype in VCAN siRNA-treated cells. We did not detect a significant effect on expression of ACTA2 (a-SMA, P = 0. 
Discussion
Higher VCAN expression was reported in leiomyoma than in myometrium, typically using bulk analysis methods such as reverse transcription PCR. Versican abundance in leiomyoma was demonstrated by western blotting and by selective proteoglycan isolation using ion exchange chromatography (11, 28) . Here, we investigated several aspects of versican content in leiomyoma. Initially, using qRT-PCR, we confirmed VCAN V0 and V1 transcript abundance in human myometrial and leiomyoma tissue. We used spatial visualization of the mRNAs for the major exons spliced to generate these isoforms, showing robust expression by leiomyoma and myometrial cells. We compared mRNA expression of the VCAN isoforms and ADAMTS protease genes between women with asymptomatic and symptomatic leiomyoma (i.e., with significantly more heavy menstrual bleeding, larger leiomyoma, and lower hemoglobin) and found upregulation of versican and specific ADAMTS genes in the symptomatic participants.
Here, we show significant proteolytic processing of versican in untreated leiomyoma. Our analysis of myometrial and leiomyoma extracts demonstrated little intact versican; we detected molecular species smaller than full-length versican V0 or V1. Intact versican was previously isolated from leiomyoma using ion exchange chromatography (11) . It is possible that our extraction method, using a detergent-rich buffer free of chaotropic agents or high salt, may have inadequately extracted intact versican, which is bound to hyaluronan and other ECM components via electrostatic interactions. However, subsequent analysis of UtSMC-hTERT and UtLMhTERT cells, including extraction of the cell layer and analysis alongside conditioned medium, failed to demonstrate intact versican isoforms despite digestion with chondroitinase ABC. Instead, comparable versican fragments were seen in tissue extracts and cell lines. Because the versican species observed were reactive with anti-DPEAAE, which recognizes versican cleaved by ADAMTS proteases, and because these proteases were indeed expressed in tissue from subjects, we conclude that ADAMTS proteases have a substantial role in versican cleavage in leiomyoma. Indeed, immunostaining with anti-DPEAAE, anti-ARRGQF, and anti-NIVSFE in myometrium and leiomyoma provided robust signals. Furthermore, versican antibody reactivity was nearly completely eliminated by VCAN knockdown in UtLMhTERT cells. These studies do not argue that the versican products that were detected resulted solely from ADAMTS cleavage because a number of proteinases are likely to be active in the extracellular milieu and could work in combination. Indeed, on the basis of the lack of detectable fragments containing NIVSFE or ARRGQF peptides on western blots, we believe that other proteases acting in concert with ADAMTS proteases may generate fragments that are too small for retention in the gel under the electrophoretic conditions used here. Nevertheless, the detection of specific neo-epitopes resulting from ADAMTS activity in situ in tissues, where such fragments may be retained, is strong evidence for their role in versican proteolysis. To determine the impact of versican and its fragments on the behavior of leiomyoma, we used VCAN RNA silencing in UtLM-hTERT cells. Despite effective VCAN silencing, there was no impact on the cellular phenotypes analyzed. In part, this could reflect the fact that much of the versican was proteolytically cleaved and therefore did not accumulate in the pericellular matrix. That the loss of versikine did not have an impact on the UtLM-hTERT cell line suggests that these cells may not have the cellular mechanisms, presently poorly understood, that are required for versikine action (27) . Recent work showed that leiomyosarcomas had considerably stronger versican immunostaining than leiomyoma (29) . The leiomyosarcoma cell line SK-LMS-1 expressed abundant VCAN and VCAN knockdown-reduced cell proliferation and migration (29) ; however, versican cleavage was not studied in this tumor.
Estrogen has long been associated with stimulation of leiomyoma growth (30) and is a target for medical treatment. Upon binding to estrogen receptor a, estrogen allows the leiomyoma to respond to progesterone through increased expression of progesterone receptors (31) . We demonstrate that VCAN knockdown in UtLMhTERT cells reduced mRNA expression of ESR1 and PGR-A. Both receptors are essential for the growth and development of leiomyoma and can therefore be potentially modulated by targeting versican. In this context, cetrorelix (21, 32) and tranilast (33) treatment of leiomyoma cells reduced versican, as well as fibronectin and collagen-1. Further studies are required to determine if manipulation of versican expression or cleavage by ADAMTS proteases is a potential nonhormonal therapeutic approach in symptomatic leiomyoma.
